| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $1,063,683 ) |
| | 2023 | 2023 | KINETA INC | 219 TERRY AVE N | SEATTLE | WA | 98109-5230 | KING | USA | R01AI141102 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | 000 | 5 | NIH | 12/6/2022 | $1,063,683 |
|
| Issue Date FY: 2022 ( Subtotal = $1,118,000 ) |
| | 2022 | 2022 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI141102 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | 000 | 4 | NIH | 12/10/2021 | $1,118,000 |
|
| Issue Date FY: 2021 ( Subtotal = $1,134,275 ) |
| | 2021 | 2021 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI141102 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | 000 | 3 | NIH | 12/15/2020 | $1,134,275 |
| | 2021 | 2020 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44CA213567 | Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics | 000 | 3 | NIH | 5/12/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,913,830 ) |
| | 2020 | 2020 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44CA213567 | Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics | 001 | 3 | NIH | 3/27/2020 | $750,000 |
| | 2020 | 2020 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI141102 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | 000 | 2 | NIH | 12/4/2019 | $1,163,830 |
| | 2020 | 2019 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44CA213567 | Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics | 000 | 2 | NIH | 2/13/2020 | $0 |
| | 2020 | 2018 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R43CA213567 | Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics | 000 | 1 | NIH | 3/24/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,120,459 ) |
| | 2019 | 2019 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI141102 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | 000 | 1 | NIH | 12/28/2018 | $1,370,459 |
| | 2019 | 2019 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI141102 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | 001 | 1 | NIH | 8/12/2019 | $0 |
| | 2019 | 2019 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44CA213567 | Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics | 000 | 2 | NIH | 2/25/2019 | $750,000 |
| | 2019 | 2018 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R43DA045413 | Development of an alpha-conotoxin RgIA analog as a novel, non-opioid therapeutic for chronic neuropathic pain | 000 | 1 | NIH | 10/30/2018 | $0 |
| | 2019 | 2017 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44AI115824 | Development of novel isoflavone drugs as broad spectrum antivirals | 000 | 2 | NIH | 3/1/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $450,000 ) |
| | 2018 | 2018 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R43DA045413 | Development of an alpha-conotoxin RgIA analog as a novel, non-opioid therapeutic for chronic neuropathic pain | 000 | 1 | NIH | 1/9/2018 | $225,000 |
| | 2018 | 2018 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R43CA213567 | Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics | 000 | 1 | NIH | 3/30/2018 | $225,000 |
| | 2018 | 2016 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R41AI122566 | Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus | 000 | 1 | NIH | 4/23/2018 | $0 |
| | 2018 | 2015 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI093387 | Antiviral Drugs for Arenaviruses | 000 | 5 | NIH | 12/7/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $817,795 ) |
| | 2017 | 2017 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44AI115824 | Development of novel isoflavone drugs as broad spectrum antivirals | 001 | 2 | NIH | 5/31/2017 | $746,345 |
| | 2017 | 2016 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R44AI115824 | Development of novel isoflavone drugs as broad spectrum antivirals | 000 | 1 | NIH | 5/25/2017 | $43,175 |
| | 2017 | 2014 | KINETA, INC. | 219 TERRY AVE N STE 300 | SEATTLE | WA | 98109-5230 | KING | USA | R01AI093387 | Antiviral Drugs for Arenaviruses | 001 | 4 | NIH | 3/20/2017 | $28,275 |
|
| Issue Date FY: 2016 ( Subtotal = $939,619 ) |
| | 2016 | 2016 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R41AI122566 | Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus | 000 | 1 | NIH | 8/9/2016 | $224,977 |
| | 2016 | 2016 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI115824 | Development of novel isoflavone drugs as broad spectrum antivirals | 000 | 1 | NIH | 6/21/2016 | $714,642 |
|
| Issue Date FY: 2015 ( Subtotal = $1,296,933 ) |
| | 2015 | 2015 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R01AI093387 | Antiviral Drugs for Arenaviruses | 000 | 5 | NIH | 7/30/2015 | $1,296,933 |
|
| Issue Date FY: 2014 ( Subtotal = $1,228,837 ) |
| | 2014 | 2014 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R01AI093387 | Antiviral Drugs for Arenaviruses | 000 | 4 | NIH | 7/24/2014 | $1,228,837 |
|
| Issue Date FY: 2013 ( Subtotal = $798,935 ) |
| | 2013 | 2013 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 000 | 5 | NIH | 6/20/2013 | $798,935 |
|
| Issue Date FY: 2012 ( Subtotal = $948,451 ) |
| | 2012 | 2012 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 002 | 4 | NIH | 8/15/2012 | $956,404 |
| | 2012 | 2012 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 002 | 4 | NIH | 8/15/2012 | -$956,404 |
| | 2012 | 2012 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 001 | 4 | NIH | 6/14/2012 | $956,404 |
| | 2012 | 2011 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 000 | 3 | NIH | 12/23/2011 | -$7,953 |
|
| Issue Date FY: 2011 ( Subtotal = $1,300,000 ) |
| | 2011 | 2011 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R43AI085691 | DEVELOPMENT OF KV1.3 CHANNEL BLOCKER SHK-186 AS A THERAPY FOR MULTIPLE SCLEROSIS | 000 | 2 | NIH | 3/14/2011 | $300,000 |
| | 2011 | 2011 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R44AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 000 | 3 | NIH | 7/18/2011 | $1,000,000 |
|
| Issue Date FY: 2010 ( Subtotal = $299,443 ) |
| | 2010 | 2010 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R43AI085691 | DEVELOPMENT OF KV1.3 CHANNEL BLOCKER SHK-186 AS A THERAPY FOR MULTIPLE SCLEROSIS | 000 | 1 | NIH | 3/31/2010 | $299,443 |
|
| Issue Date FY: 2009 ( Subtotal = $285,415 ) |
| | 2009 | 2009 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R43AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 001 | 2 | NIH | 8/10/2009 | $285,415 |
| | 2009 | 2008 | KINETA INC | 307 WESTLAKE AVENUE NORTH | SEATTLE | WA | 98109 | KING | USA | R43AI081335 | AGONISTS OF THE RIG-I INNATE IMMUNE PATHWAY | 000 | 1 | NIH | 10/13/2008 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $299,892 ) (Continued on the next page) |
|
